AbstractTwenty-two children with immune thrombocytopenic purpura (ITP) with long-lasting thrombocytopenia, adversely affecting their quality of life, were treated with a reduced rituximab regimen in order to eliminate B cells producing anti-platelet antibody. A single dose of rituximab resulted in a response rate similar to that reported for cases in which 4 doses of rituximab were used.
Figures & Tables
Vol. 90 No. 2 (2005): February, 2005 : Letters to the Editor
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com